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Abstract
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Treatment of bovine pulmonary arterial endothelial cells in culture with the phase II enzyme
inducer sulforaphane (5 μM, 24 hrs; sulf-treated) increased cell lysate NQO1 activity by 5.7 ± 0.6
(mean ± SEM) fold, but intact cell NQO1 activity by only 2.8 ± 0.1 fold compared to control cells.
To evaluate the hypothesis that the threshold for sulforaphane induced intact cell NQO1 activity
reflects a limitation in the capacity to supply NADPH at a sufficient rate to drive all the induced
NQO1 to its maximum activity, total KOH extractable pyridine nucleotides were measured in cells
treated with duroquinone to stimulate maximal NQO1 activity. NQO1 activation increased
NADP+ in control and sulf-treated cells, with the effect more pronounced for the sulf-treated cells,
in which the NADPH was also decreased. Glucose-6-phosphate dehydrogenase (G-6-PDH)
inhibition partially blocked NQO1 activity in control and sulf-treated cells, but G-6-PDH
overexpression via transient transfection with the human cDNA alleviated neither the restriction
on intact sulf-treated cell NQO1 activity nor the impact on the NADPH/NADP+ ratios.
Intracellular ATP levels were not affected by NQO1 activation in control or sulf-treated cells. An
increased dependence on extracellular glucose and a rightward shift in the Km for extracellular
glucose was observed in NQO1 stimulated sul-ftreated vs control cells. The data suggest that
glucose transport in the sulftreated cells may be insufficient to support the increased metabolic
demand for pentose phosphate pathway generated NADPH as an explanation for the NQO1
threshold.
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Introduction
NAD(P)H:quinone oxidoreductase (NQO1) is a two-electron quinone reductase present in a
wide range of tissue and cell types including the pulmonary endothelium and other lung
cells [1-7]. This predominately cytosolic (>90%) phase II enzyme catalyzes reduction of a
wide spectrum of physiological, pharmacological and toxicological quinones and other
redox active substances [1, 8, 9]. Depending on the chemical properties of the electron
acceptor and the reaction product formed, NQO1 activity may mediate protective and antioxidant or toxic and pro-oxidant effects [1, 4, 8, 10-15].
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Among the various roles in which NQO1 has been implicated, one is as a target for
bioreductive activation of certain anticancer drugs and antioxidants and as a means of
xenobiotic detoxification, wherein induction or genetic overexpression represent potential
means to exploit these functions [12, 14, 16-20]. However, increases in NQO1 enzyme
levels do not necessarily result in proportional increases in cellular effects (e.g., toxicity or
antioxidant activity) of substances subject to NQO1 activation [12, 19, 21-28]. This
phenomenon manifests itself as an upper threshold beyond which further increases in NQO1
levels do not result in enhanced effects of the NQO1-activated substrates [12, 19, 21-28].
In general, studies of the threshold effect have been limited by the lack of methodologies for
quantifying intact cell NQO1 activity. Thus, whereas NQO1 activity is usually measured in
cell lysates using a classical NQO1 enzyme assay, intact cell activity has largely been
inferred from functional outcomes (e.g., toxicity or antioxidant protection) of NQO1
catalyzed activation of the compound under study. The only study we know of that included
measurements of intact cell NQO1 activity was limited by the inability to obtain maximal
activity using the chosen substrate [29]. The present study was motivated by the need to
develop a quantitative basis for evaluating the threshold effect, wherein a further
understanding of this phenomenon may suggest therapeutic strategies for increasing the
efficacy of NQO1 targeted therapeutics.
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In the present study, we sought to address the problem using an approach we developed for
quantifying NQO1 activity in intact pulmonary arterial endothelial cells in culture. It
involves the addition of the quinone, duroquinone (DQ), to the medium surrounding the
cells and measuring the appearance rate of the two electron reduction product,
durohydroquinone (DQH2) using a secondary redox indicator. We have previously used this
methodology to evaluate NQO1 kinetics, induction via hyperoxic exposure and electron
donor preference in intact pulmonary arterial endothelial cells [2, 30, 31]. A variation of the
method has also been used to evaluate NQO1 activity in the isolated perfused rodent lung
[3].
Therefore, the overall objective of the present study was to quantify both intact cell and cell
lysate NQO1 activity in control and sulforaphane induced (sulf-treated, 5 μM, 24 hrs)
pulmonary arterial endothelial cells. The expectation was that NQO1 would be induced as a
component of the overall phase II enzyme induction observed with sulforaphane treatment
in other cell and organ systems, but not yet reported for pulmonary endothelial cells. Then,
comparison of the fold differences in NQO1 activity in the intact cell and cell lysate assays
would allow for determination of a threshold in the sulf-treated cells. If a threshold was
observed, a second objective was to ask whether it could be explained by a limitation in the
Free Radic Biol Med. Author manuscript; available in PMC 2013 December 04.
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capacity to generate sufficient electron donor to drive all the sulforaphane induced cell
lysate NQO1 to its maximal intact cell rate. This concept was motivated by our previous
studies implicating NADPH as the endogenous NQO1 electron donor in pulmonary arterial
endothelial cells and by observations that, in general, quinone reduction appears to promote
a drive to generate NADPH in other cell types [30, 32-34]. The approach was to evaluate the
impact of NQO1 activation on cellular pyridine nucleotides, and the dependence of NQO1
activity on glucose-6-phosphate dehydrogenase (G-6-PDH) activity and extracellular
glucose concentration.
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Endothelial cells were selected for study because they are among the cell types that have
relatively high NQO1 expression, which is perhaps not surprising given that they are in
direct contact with blood-borne redox active xenobiotics, pharmacological and physiological
quinones and other NQO1 substrates [7]. In this regard, pulmonary endothelial NQO1 may
be of particular importance because of the large pulmonary endothelial surface area and
position in the circulation. This property confers the ability to alter the redox status and
disposition of redox active compounds during passage of the blood from the venous to the
systemic arterial circulations [3, 35]. Sulforaphane was used as the phase II enzyme inducer
because the lung is a key target organ of ingested dietary derived isothiocyanates, and there
is intense interest in this class of compounds as cancer preventive, anti-inflammatory and
oxidative stress protective agents in the lung, cardiovascular and other organ systems [20,
36-43]. In the vascular endothelium and lung, angiogenesis, inflammation, proliferation,
carcinogenesis and other processes have been implicated as targets for manipulation by
sulforaphane [38, 44-49]. From an experimental perspective, sulforaphane exposure also
provides a model to evaluate the net effects of various phase II enzyme induced adaptive
changes in cellular metabolism and redox function on intact cell NQO1 activity.

Materials and Methods
Materials
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3-Potassium hexacyanoferrate (III) (hereafter referred to as
or ferricyanide),
2,3,5,6-tetramethyl-1,4-benzoquinone (duroquinone, hereafter referred to as DQ),
epiandrosterone (EPI), N-2-hydroxyethylpiperazine-N′-2-ethanesulfonic acid (HEPES),
dicumarol, ATP and other chemicals, unless otherwise noted, were purchased from Sigma
Chemical (St. Louis, MO). Sulforaphane was purchased from LKT Laboratories (St Paul,
MN). Trypsin, penicillin-streptomycin, RPMI 1640 tissue culture medium, fetal calf serum,
NuPAGE LDS sample buffer, 4-12% gradient Nu-PAGE Bis-Tris gels, MES-SDS running
buffer and Lipofectamine 2000 were from Invitrogen (Grand Island, NY). Biosilon beads
were from Nunc (Roskilde, Denmark). Pyridine nucleotide standards for HPLC were
purchased from Boehringer Mannheim (Indianapolis, IN). Immunopure horseradish
peroxidase and the SupersignalWest Pico Chemiluminescent substrate were from ThermoFisher Scientific (Rockford IL). The NQO1 inhibitor ES936 was the kind gift of Drs. David
Siegel and David Ross (School of Pharmacy, University of Colorado Health Sciences
Center, Denver, CO). The cDNA for human G-6-PDH was generously provided by Dr
Margaret Briehl, University of Arizona [50].
Endothelial cell culture and sulforaphane treatment
Bovine pulmonary arterial endothelial cells were isolated from segments of calf pulmonary
artery obtained from a local slaughterhouse, and cells between passages 4 and 20 were
cultured to confluence on Biosilon microcarrier beads (mean diameter 230 μm; surface area
255 cm2/gm beads) in magnetic stirrer bottles (Techne Inc., Burlington, N.J.) containing
RPMI 1640 medium supplemented with 20% fetal calf serum, 100 U/ml penicillin, 100 μg/
ml streptomycin and 30 mg/ml L-glutamine as previously described [2, 31]. The cells were
Free Radic Biol Med. Author manuscript; available in PMC 2013 December 04.
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99.5% positive for DiO-acetylated-low density lipoprotein (Biomedical Technologies)
uptake as measured by fluorescence activated cell sorting and exhibited cobblestone
morphology as observed by phase contrast microscopy. Each passage of confluent cell
cultures were separated into two groups, one of which was incubated in sulforaphane (5
μM), designated as sulf-treated, containing medium and one in medium alone for 24 hours
before carrying out the described studies.
Protocol for measuring NQO1 activity in intact cells
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DQ-mediated reduction of the cell membrane impermeant secondary electron acceptor,
ferricyanide, was used to measure intact cell NQO1 activity, as previously described [2, 30,
31]. Approximately 0.2 - 0.3 ml packed volume of cell-coated beads were aliquoted from the
stirred culture flasks into spectrophotometric cuvettes. After the cell-coated beads had
settled, they were washed three consecutive times by resuspension in 3 ml of Hank's
Balanced Salt Solution (HBSS) containing 10 mM HEPES, pH 7.4 and 5.5 mM glucose
(HBSS/HEPES), allowing the beads to settle between each wash. The cell-coated beads
were resuspended in 3 ml of HBSS/HEPES only (control) or HBSS/HEPES containing the
various inhibitors or treatment conditions specified in the Results section and figure legends,
and incubated with mixing on a Nutator mixer at 37°C for 10 min. Then the cell-coated
beads were resuspended in 3 ml of fresh HBSS/HEPES containing 600 μM ferricyanide and
DQ (at varying concentrations indicated in the text and figure legends) including the same
treatments present during the 10-min pre-treatment incubation. The cell suspensions were
mixed on a Nutator mixer at 37°C, and periodically the mixing was stopped, the cell-coated
beads allowed to settle at the bottom of the spectrophotometric cuvettes out of the
spectrophotometer light path, and the absorbance of ferricyanide in the medium measured at
421 nm using a Beckman Model DU 7400 spectrophotometer. The amount of the
ferricyanide reduction product, ferrocyanide
in each sample was calculated
from the decrease in ferricyanide absorbance at each time point (extinction coefficient 1.0
mM−1 · cm−1). DQ-mediated ferricyanide reduction rates were determined from linear
regression fits of the individual ferricyanide versus time curves [2]. The background rates of
cell mediated ferricyanide reduction in the absence of DQ were subtracted from the
individual rates obtained in their presence, normalized to the cell protein, and then combined
to obtain mean rates. The DQ reduction rates were calculated as one-half the mean
ferricyanide reduction rates. At the end of each experiment, the microcarrier beads were
dried and weighed to determine the cell culture surface area for purposes of normalizing the
data between experiments.

NIH-PA Author Manuscript

For measuring the dependence of intact cell NQO1 activity on the glucose concentration in
the extracellular medium, the protocol was as described above except that wash solution was
HBSS containing 10 mM HEPES and 2 mM pyruvate, pH 7.4, and either 0, 0.1, 0.3, 2.5 or
5.5 mM glucose. Following the washes, the cell coated beads were resuspended in the same
medium in which they were washed, and with the DQ and ferricyanide as described above.
Measurement of DQ concentration in extracellular medium
Control or sulf-treated cells were incubated with 1 μM DQ for 30 min, the medium was
removed from the cells and added to fresh control cells only. The DQ reduction rates of the
two sets of control cells were measured as described above.
Cell lysate NQO1 and G-6-PDH activities
Cell lysates were prepared from cell-coated microcarrier beads by sonication (3 pulses of 15
sec each with the power output set to 6 watts using a Microson Ultasonic Cell Disrupter,

Free Radic Biol Med. Author manuscript; available in PMC 2013 December 04.
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Farmington, NY) of ∼ 0.2 ml of packed cell-coated beads on ice in 1 ml of 25 mM Tris-HCl
buffer, pH 7.4.
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NQO1 activity in cell lysates was determined using either the classical NQO1 electron
acceptor 2,6-dichlorophenolindophenol (DCPIP) or DQ. DCPIP (50 μM) reduction was
measured spectrophotometrically at 600 nm (extinction coefficient 21.0 mM−1 · cm−1) at
25°C following the addition of cell lysate fraction (∼10 μg protein) to a reaction mixture
containing 25 mM Tris-HCl, 0.02% bovine serum albumin, 0.01% Tween 20, 5 μM flavin
adenine nucleotide (FAD) and 200 μM NADPH, pH 7.4, as previously described [2]. The
difference between the reaction rates in the absence and presence of 10 μM dicumarol was
used to calculate the NQO1 activity. When cell lysate NQO1 activity was measured using
DQ, the buffer was the same as above with DQ (50 μM) substituted for the DCPIP and 45
μg/ml Immunopure horseradish peroxidase, 0.8 mM H2O2 and 0.15 mM NADPH added to
the reaction mixture (total volume, 1 ml). The reaction was initiated by the addition of 50 μl
of cell lysate and the decrease in NADPH absorbance over time at 25°C was measured
spectrophotometrically at 340 nm and in the presence and absence of dicumarol. NADPH
absorbance was used to calculate the NADPH oxidation rate using a molar extinction
coefficient of 6.22 mM-1 · cm-1. The difference between the reaction rates in the absence
and presence of 10 μM dicumarol was used to calculate the NQO1 activity.
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G-6-PDH activity was determined by measuring the rate of NADPH generation from
NADP+ spectrophotometrically at 340 nm (extinction coefficient 6.22 mM−1 (x000B7)
cm−1) at 25°C following the addition of the cell lysate fraction (∼75 μg protein) to a
reaction mixture containing 55mM Tris-HCl (pH 7.4), 3.3 mM MgCl2·6H2O, 3.3 mM
glucose-6-phosphate and 2.0 mM NADP+[51].
The reaction rates were normalized to the cell lysate protein as measured by the Bio-Rad or
BCA protein assays.
Immunoblotting for NQO1
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Portions of control and sulf-treated cell lysates, prepared as described above, or purified
recombinant human NQO1 (hrNQO1, 0.5 ng protein) were subjected to SDS-PAGE
electrophoresis using Invitrogen's NuPAGE LDS sample buffer, 4-12% gradient Nu-PAGE
Bis-Tris gels and MES-SDS running buffer, as we previously described [3, 6]. The amounts
of cell lysate protein loaded onto the gels is described in the Figure 3 legend. The separated
proteins were transferred to a nitrocellulose membrane, and incubated for 1 h in Trisbuffered saline containing 0.1% Tween 20 and 2% bovine serum albumin, the latter as a
blocking agent. The membrane was then incubated sequentially in a 1:1000 dilution of
primary antibody (polyclonal goat anti-rabbit NQO1), a 1:20,000 dilution of secondary
antibody (rabbit anti-goat IgG-horseradish peroxidase conjugate) and the Supersignal West
Pico Chemiluminescent substrate. The image was captured and band intensities quantified
using a Kodak IS 2000 MMT ImageStation and Image Station software. NQO1 protein on
the blots was quantified using the hrNQO1 as a standard under conditions in which the band
intensities vs μg protein loaded relationship was in the linear range of intensities. The NQO1
protein amounts were normalized to total cell lysate protein loaded onto the lanes to obtain
the amount of NQO1 protein per mg cell lysate protein.
Pyridine nucleotide and ATP high performance liquid chromatography (HPLC)
Cell-coated beads were washed free of growth medium as described above. The washed
cell-coated beads were aliquoted into conical bottom centrifuge tubes and incubated in
HBSS/HEPES without or with DQ for 15 min at 37°C on a Nutator. Following the
incubation, the cell-coated beads were allowed to settle, the experimental medium was

Free Radic Biol Med. Author manuscript; available in PMC 2013 December 04.
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removed, and the pyridine nucleotides extracted with ice cold KOH prior to HPLC as
previously described [30]. Pyridine nucleotide and ATP levels were normalized to cm2 cell
culture surface area.
Transfection with cDNA for G-6-PDH
G-6-PDH overexpressing bovine pulmonary arterial endothelial cells were obtained by
transient transfection with a cDNA for human G-6-PDH, kindly provided by Dr Margaret
Briehl, University of Arizona [50]. The G-6-PDH cDNA was subcloned into the pcDNA3.1
vector and the sequence confirmed using PCR. Cells were transfected using Lipofectamine
2000 according to the manufacturer's protocol. Successful transfection was confirmed 2 days
later by enzyme assay for G-6-PDH in cell lysates. As controls for the G-6-PDH transfected
cells, cells were treated with Lipofectamine 2000 in the absence of the vector (mock
transfected). After 2 days, cells were further incubated in cell medium with or without
sulforaphane (5 μM) for 24 hours.
Additional measurements
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As a measure of cell viability, lactate dehydrogenase (LDH) activity in the treatment
medium and in the cells at the end of each experimental protocol was determined, and the %
total LDH release calculated, as previously described [2]. The total cell LDH activities for
control and sulforaphane cells were 3.44 ± 0.08 and 3.58 ± 0.05 (mean ± SEM) units per μg
cell protein, with no significant difference between the activities, or under the different
experimental conditions (p>0.05, t-test). The % LDH release did not exceed 1.58 ± 0.37% of
total cell LDH for all the studies combined, with no significant differences between
conditions (p>0.05, ANOVA). To normalize the data for comparisons between studies, the
protein content of the cells in each experiment was measured using the BioRad or Pierce
BCA protein assays, previously described for the BioRad assay in [2]. One cm2 of cell
surface area of confluent control or sulf-treated endothelial cells cultured on the Biosilon
microcarrier beads contained 25.5 ± 0.3 μg (mean ± SEM) protein.
Statistical analysis
Data are expressed as mean ± standard error (mean ± SEM). Statistical analysis was
performed using SigmaStat (Jandel Scientific, San Rafael, CA). Differences between groups
were evaluated using the t-test, or ANOVA followed by Tukey test.

Results
NIH-PA Author Manuscript

Figure 1 illustrates the approach used to measure NQO1 activity in intact pulmonary arterial
endothelial cells, which involves the addition of DQ and ferricyanide to the medium
surrounding the cells, as previously described [2, 30, 31]. The method relies on the fact that
both DQ and its hydroquinone (DQH2) are freely membrane permeant, whereas both
ferricyanide and its reduction product, ferrocyanide, are cell membrane impermeant [2, 30,
31]. DQ enters the cells and is reduced to DQH2 via NQO1 at the expense of intracellular
NADPH [30]. Then, the DQH2 leaves the cell where it is virtually instantaneously reduced
by the ferricyanide in the extracellular medium. Under these reaction conditions, DQ is
continually regenerated in the extracellular medium, maintaining steady state DQ reduction
kinetics as reflected by the zero order ferricyanide vs time progress curves. The ferricyanide
reduction remains zero order until the ferricyanide is exhausted, as expected of a secondary
electron acceptor that is essentially irreversibly reduced and does not influence the primary
reduction rate [2, 30, 31]. In addition the ferricyanide concentration is sufficient to act as an
extracellular sink for intracellular NQO1 generated DQH2. Taken together, the zero order
ferricyanide reduction rates provide measurements of intracellular NQO1 activity [2, 30,
31].
Free Radic Biol Med. Author manuscript; available in PMC 2013 December 04.
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Figure 1 shows the DQ-mediated ferricyanide reduction rates versus time for control (Figure
1A) and sulf-treated (Figure 1B) cells for a range of DQ concentrations. Also shown is that
ferricyanide alone is not substantially reduced in the absence of DQ. Figures 1A and B also
show that the competitive NQO1 inhibitor, dicumarol, blocks ferricyanide reduction in the
presence of the highest DQ concentration used, 50 μM, for both control and sulf-treated
cells.
Figure 2 shows the dependence of the DQ reduction rates, calculated from the data in Figure
1, on DQ concentration (0 - 50 μM) for control and sulf-treated cells. The reduction rates
increased in a concentration-dependent manner over the range of 1-10 μM DQ, reaching a
maximum for both cell conditions at ∼10 μM DQ (Figure 2). At the maximal rates, the
apparent NQO1 activity was about ∼3 fold higher for the sulf-treated than control cells.
However, at DQ concentrations of 1 and 3 μM, the difference between the reduction rates
for the control and sulf-treated cells was further diminished. One possible explanation for
the observations at low DQ concentrations is a sulforaphane induced increase in DQ
conjugating enzymes, which could decrease the free DQ concentration and hence the
apparent DQ reduction rate. However, there was no detectable difference between the DQ
concentrations in the medium of control and sulf-treated cells incubated with 1 μM DQ
under the study conditions (p > 0.05; n = 3; data not shown).
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Figure 2 also shows that dicumarol blocked DQ reduction at all DQ concentrations studied
for both control and sulf-treated cells. This is consistent with the data shown for dicumarol
with 50 μM DQ in Figures 1A and B. Figure 2 additionally shows the inhibitory effect of the
irreversible NQO1 inhibitor, ES936, on DQ reduction for the sulf-treated cells, as we have
previously demonstrated for control cells [30, 31]. The nearly complete inhibitory effect of
both NQO1 inhibitors is consistent with the DQ reduction rate measurement as a selective
NQO1 activity indicator in intact pulmonary arterial endothelial cells. All further studies
were carried out at 50 μM DQ to achieve maximal intact cell NQO1 activity.
Figure 3 shows immunoblots for NQO1 protein in control and sulf-treated treated cells,
wherein the blots in Figure 3A were loaded with equal amounts of control and sulf-treated
cell lysate protein (20 μg) and those in Figure 3B with 10 times more control than sulftreated cell lysate protein, that is, 20 vs 2 μg, respectively. Figure 3C shows the total NQO1
on the blots calculated from the lane intensities in Figure 3B, and Figure 3D shows that there
was 7 times more NQO1 protein per mg total cell protein for the sulf-treated vs control cells.
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The maximal intact cell NQO1 activity, measured as DQ-mediated ferricyanide reduction,
was 2.8 ± 0.1 (mean ± SEM) fold higher in sulf-treated than control cells (Figure 4A). The
sulf-treated cell lysate activity, measured using either DCPIP or DQ as the electron acceptor,
was 5.7 ± 0.6 (mean ± SEM) or 5.1 ± 0.5 (mean ± SEM) fold higher, respectively, than the
control cell lysate activity (Figure 4B). There was no significant difference between the fold
increases observed with the two electron acceptors (p > 0.05, t-test). Figure 4C shows the
relationship between the sulforaphane induced fold increase in cell intact cell NQO1 activity
vs the fold increase in cell lysate NQO1 activity for all 20 pairs of control vs sulf-treated
cells in Figures 4A and B. The sulforaphane induced increase in intact cell NQO1 activity
was capped at 3.6 fold even when the increase in cell lysate activity ranged as high as 11
fold.
The apparent limitation on intact sulf-treated cell NQO1 activity is further emphasized by
the observation that when the cells were subjected to H2O2 as an oxidative stress, the
maximal intact cell NQO1 activity was depressed in the sulf-treated but not control cells
(Figure 5). The depression was not attributable to any direct effect of H2O2 on intrinsic
NQO1 activity insofar as there was no detectable difference in NQO1 activities in cell

Free Radic Biol Med. Author manuscript; available in PMC 2013 December 04.

Bongard et al.

Page 8

NIH-PA Author Manuscript

lysates from control and H2O2 treated cells (p>0.05, t-test, data not shown). There was also
no difference in the G-6-PDH activities in lysates from control and H2O2 treated cells
(p>0.05, t-test, data not shown), and no decrease in cell viability (% LDH release) due to
H2O2 treatment (p>0.05, t-test, data not shown).
Since one mechanism by which H2O2 exerts an oxidative stress in endothelial cells is to
increase the demand on the pentose phosphate pathway, we sought more direct evidence for
involvement of this pathway in the intact cell NQO1 activity [52, 53]. Figure 6 shows that
the G-6-PDH inhibitor EPI depressed intact control and sulf-treated cell NQO1 activity. The
EPI effect on the control cells was consistent with previous studies [30].
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To evaluate the impact of NQO1 stimulation on pyridine nucleotide redox status, total cell
KOH extractable NAD+, NADP+, NADH and NADPH were measured in the absence and
presence of 50 μM DQ. In both the control and sulf-treated cells, DQ increased NADP+ and
in the sulf-treated cells, a decrease in NADPH was also detected (Figures 7 A and C). The
NADPH/NADP+ ratios decreased for both the control and sulf-treated cells, wherein the
decrease was more pronounced for the sulf-treated cells (Figure 7E). Although the sulftreated cells also had lower NAD+ than the control cells when DQ was present, there was no
detectable effect on NADH levels or the NADH/NAD+ redox pair in control or sulf-treated
cells (Figure 7B, D and F). The observations for the control cells were consistent with our
previous study revealing a tighter coupling of intact cell NQO1 activity to the intracellular
NADPH/NADP+ than the NADH/NAD+ redox pair, thereby implicating NADPH as the
endogenous NQO1 electron donor [30].
Although NADP+ was previously ruled out as an NQO1 inhibitor in studies of isolated rat
liver cytosol NQO1, the more elevated NADP+ in NQO1 activated sulf-treated as compared
to control cells raised the question of NADP+ as a potential NQO1 inhibitor [54]. When cell
lysate NQO1 assays were carried out with the usual 0.20 mM NADPH in the absence or
presence of NADP+ (0.06, 0.20, 0.60 or 2.00 mM), there was no detectable inhibition of
sulf-treated cell lysate NQO1 activity at any NADP+ concentration studied (p < 0.05; n =7
different cell populations each NADP+ concentration; data not shown). There was also no
detectable inhibition of control cell lysate NQO1 activity at 0.06, 0.20 or 0.60 mM NADP+
(p > 0.05; n =7 different cell populations each NADP+ concentration; data not shown); a 23
± 3 (mean ± SEM) % inhibition of control cell lysate activity was observed only at the
highest NADP+ concentration studied (2.00 mM; p < 0.05; n = 7 different cell populations;
data not shown).
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The Figures 5-7 data suggested that overexpressing G-6-PDH in the sulf-treated cells might
represent a means to overcome the restriction on the induced NQO1 activity. Figure 8A
shows that the baseline G-6-PDH activities in the control and sulf-treated cell lysates were
not detectably different and that transient transfection with a cDNA for human G-6-PDH
increased cell lysate G-6-PDH activity to the same extent in both control and sulf-treated
cells (Figure 8A). There was no detectable effect of G-6-PDH overexpression on cell lysate
NQO1 activity in control or sulf-treated cells, and therefore no compensatory effects of the
transfection on intrinsic NQO1 activity (Figure 8B). However, G-6-PDH overexpression did
not facilitate intact cell NQO1 activity in either control or sulf-treated cells (Figure 8C).
Figure 9 shows that G-6-PDH overexpression also did not mitigate against the DQ induced
effects on NADP+, NADPH or the NADPH/NADP+ ratios seen in the absence of
overexpression. That is, the Figure 9 data qualitatively reproduce the patterns seen in the
NADP(H) data (Figure 7A, C, E) in the absence of G6PDH overexpression.
Since the threshold for intact sulf-cell NQO1 activity could not be attributed to limitations in
G-6-PDH activity, and intracellular ATP was not detectably altered in the presence of DQ
Free Radic Biol Med. Author manuscript; available in PMC 2013 December 04.
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(50 μM) to activate NQO1 in either control or sulf-treated cells (t-test, p>0.05; data not
shown), we asked whether more proximal processes contributing to intact cell NADPH
regeneration capacity and NQO1 driven DQ reduction, e.g., glucose transport, were
implicated. One means of identifying mechanisms involved in control of glucose utilization
in neuronal and other cell types has been to evaluate the dependence of intracellular
glucose-6-phosphate generation on the extracellular glucose concentration [55].
Figure 10 shows the dependence of intact control and sulf-treated cell NQO1 activities on
the glucose concentration in the extracellular medium. The sulf-treated cell NQO1 activity
was dramatically more sensitive to limiting the extracellular glucose concentration. To
emphasize this point, the difference between the control cell NQO1 activities at 0 and 5.5
mM glucose comprised a total of only 3.3 nmol DQ reduced per min per mg cell protein;
this difference was an order of magnitude higher for the sulf-treated cells (34.2 nmol DQ
reduced/min/mg cell protein). Furthermore, the apparent Km for extracellular glucose was
shifted to the right for the sulf-treated as compared to control cells.
The studies in Figures 1 – 9 were all carried out at 5.5 mM glucose. Additional studies in
which extracellular glucose was increased to 11 or 22 mM resulted in no further increase in
NQO1 activity beyond that observed with 5.5 mM glucose for either control or sulf-treated
cells (p > 0.05; data not shown).
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Discussion
The study showed that exposure of pulmonary arterial endothelial cells to sulforaphane (5
μM, 24 hrs) increased cell lysate NQO1 activity and protein levels, wherein the quantitative
increases were reasonably consistent with each other. Furthermore, the study made use of an
intact cell NQO1 activity assay, to our knowledge the first such assay to provide quantitative
information at maximal NQO1 activities, to show that intact cell NQO1 activity was also
elevated in sulf-treated cells. However, the increase in intact cell activity did not increase to
the extent predicted from the cell lysate activity measurements. Importantly, the magnitude
of this restriction was independent of whether the cell lysate assay was carried out using the
classical NQO1 electron acceptor DCPIP or the electron acceptor used in the intact cell
assay, DQ. The implication is that the threshold phenomenon in the sulf-treated pulmonary
endothelial cells cannot be assigned to a difference in electron acceptor preference of any
induced NQO1 isoform, should it exist in the pulmonary arterial endothelial cells. Thus, our
study provides the first direct, quantitative evidence of an NQO1 activity threshold in
pulmonary endothelial or any other intact cells.
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The availability of a quantitative intact cell NQO1 activity assay was paramount for
evaluation of a threshold effect. The assay we developed is such a powerful and unique tool
because it was designed to optimize the specificity for NQO1 and because it provides rates
for the maximal intact cell NQO1 activity. The specificity is revealed by observations that
the vast majority of DQ reduction at all DQ concentrations studied is sensitive to two
mechanistically different NQO1 inhibitors, the competitive inhibitor dicumarol and the
irreversible inhibitor ES936 (present study and [31]). Secondly, ferricyanide acts as a sink
for the cell generated DQH2, minimizing its intracellular re-oxidation via mitochondrial
electron transport complex III or its conjugation via other phase II enzymes [31]. Finally,
both DQ and DQH2 are relatively stable as compared to other quinone-hydroquinone pairs
with regard to autoxidation-comproportionation or redox cycling [31]. Thus, under the
experimental conditions described, the dominating reactions involving DQ and DQH2 are
reduction via NQO1 and re-oxidation via ferricyanide, respectively. The specificity of the
DQ-ferricyanide assay system for intact cell NQO1 activity helped to ensure that regardless
of whether sulforaphane affected expression of other quinone reductases and/or other redox
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and metabolic processes, the potential for such alterations to influence the measurement
were minimized [38].
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The magnitude of the NQO1 activity threshold is revealed by the Figure 2 and 4 studies. In
Figure 2, the dotted line illustrates the control cell DQ reduction rates multiplied by 5.7, the
increase predicted if the intact sulf-treated cell activity increased in direct proportion to the
cell lysate activity. Instead, the maximum sulf-treated cell NQO1 activities were only about
half that predicted from the cell lysate activities. Although the remaining studies focused
primarily on the maximal NQO1 activities, using 50 μM DQ, it is intriguing to note that at
DQ concentrations that stimulate only sub-maximal activation (below 10 μM), the threshold
is exaggerated to the extent that there is little detectable difference between the control and
sulf-treated cells. These observations emphasize the importance of taking electron acceptor
concentration and extent of NQO1 activation into consideration when evaluating a possible
threshold for intact cell or organ NQO1 activity.
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In Figure 4, the magnitude of the threshold is revealed by the relationship between the fold
changes in cell lysate and intact cell NQO1 activities. All of the symbols lie below the line
of identity, included to emphasize the point that although the cell lysate NQO1 activity
increased up to 11 fold for the individual pairs of control and sulf-treated cell populations
studied, the increase in intact cell activity was restricted to at most a 3.6 fold increase for
any given pair. That the range achieved in the fold increases for the cell lysate activities is
much greater than the range that can be attained for the intact cell activities is a
manifestation of a restriction, or threshold, for intact cell NQO1 activity.
Previous explanations for the threshold effect have included, in cases where the
measurement consisted of a toxicity index, saturation of the lesion being measured (e.g.,
formation of cytotoxic DNA crosslinks), limitation in substrate uptake or metabolism and
restriction in electron donor supply [19, 24, 26]. In the present studies, lesion saturation is
not pertinent since we measured NQO1 activity itself rather than a functional consequence
thereof. A limitation in substrate uptake or metabolism is also not relevant since the DQ
concentration vs intact cell NQO1 activity measurements included DQ concentrations that
achieved maximal activity. DQ and DQH2 cell membrane permeability are virtually
unlimited and nearly all the DQ (in the absence or presence of ferricyanide) initially added
to the cells can be accounted for in the extracellular medium or bound to the experimental
plasticware at the end of the 30 min incubations with the cells ([31] and present study).
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Several observations suggested that a limitation in the capacity to regenerate NADPH could
contribute to explaining the sulf-treated cell NQO1 threshold. NQO1 activation increased
cellular NADP+ levels and decreased the NADPH/NADP+ ratios in both control and sulftreated cells. The effects were more pronounced in sulf-treated cells, for which a depression
in NADPH was additionally detected. One interpretation is that NQO1 activation placed a
higher demand on the cells for NADPH in the sulf-treated cells because of the induced
NQO1. That the effect was more dramatically revealed in the NADP+ and NADPH/NADP+
ratios than in the NADPH itself might be explained by first noting that the measurements
were of total KOH extractable pyridine nucleotides. Whereas the presumption is that the
total cell pyridine nucleotide levels reflect changes within the cytosol when cytosolic
processes are targeted, the measurement does not take into account intracellular
compartmentalization or macromolecular binding of coenzymes [56, 57]. Thus, the
magnitude of the impact on the NADPH pool supplying the NQO1 may be masked in the
total cell measurement. Secondly, the zero order ferricyanide vs time progress curves in
Figure 1 imply steady state DQ reduction kinetics and hence a steady state NADPH
regeneration rate throughout the reaction time course [31]. The implication is that new
steady state pyridine nucleotide levels are attained upon addition of DQ and ferricyanide to
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the cells, with the change from control occurring too rapidly to be detected on the time
course of the measurements.
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Cells challenged with quinones have been reported to mobilize cytosolic and mitochondrial
sources of pyridine nucleotides via a network of metabolic processes including
interconversion reactions in an attempt to maintain NADPH levels [32-34]. For example, in
colon epithelial cells, quinone treatment increased NADP+ at the expense of NAD+,
consistent with our observations [32]. Whereas the observation that EPI depresses intact cell
NQO1 activity implicates the pentose phosphate pathway as a key source of NADPH in
pulmonary endothelial cells, the EPI-insensitive NQO1 activity suggests the potential for
contributions to cytosolic NADPH from such alternate pathways, e.g., cytosolic isocitrate
dehydrogenase and/or malic enzyme. While it is also possible that DQ redox cycling
contributed to changes in NADPH/NADP+ balance, DQ is relatively inactive in this regard
as compared to other redox cycling quinones, and if anything, we would anticipate the sulftreated cells to be more resistant to such depletion due to induction of an array of phase II
antioxidant enzymes.
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The dampening effect of H2O2 on sulf-treated but not control cell activity further suggested
that the threshold might be attributable to a limitation in the capacity to supply NADPH. The
effect of H2O2 was not attributable to NQO1 or G-6-PDH inactivation, implying an indirect
mechanism. Several known effects of H2O2 involve an impact on NADPH, for example,
H2O2 increases the demand on the endothelial cell pentose phosphate pathway as a means to
provision the glutathione redox cycle with NADPH [52, 53]. Thus, we suggest that when
both H2O2 and DQ are present, the glutathione redox cycle and NQO1 are in competition for
NADPH. The competition is intensified in the sulf-treated cells due to the induced NQO1
and NQO1 activity is compromised, unmasking a threshold for the NADPH regeneration
capacity. Other effects of H2O2 in vascular endothelial and other cell types that could
compromise NADPH include activation of poly(ADP- ribose) polymerase 1 (PARP-1),
which depletes ATP and inhibition of glucose dependent ATP synthesis [58-60].
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Interpreting the NQO1 mediated decrease in the sulf-treated cell NADPH/NADP+ ratio as a
reflection of a limitation in NADPH regeneration capacity suggested G-6-PDH
overexpression as a possible means for overcoming this restriction. This approach was
motivated by observations that transfection with recombinant adenovirus encoding G-6PDH cDNA enhanced vascular endothelial cell eNOS activity, nitric oxide production and
cell proliferation and angiogenesis, presumably via increased capacity to provide NADPH
[61]. In addition, in vascular endothelial, NIH 3T3 and HeLa cells, G-6-PDH overexpression
improved resistance to oxidative stress, attributed to enhanced NADPH for maintenance of
glutathione redox cycle [62-64]. Nevertheless, G-6-PDH overexpression did not increase
maximal NQO1 activity in either the control or sulf-treated cells. A limitation in free
NADP+, which at least in Ehrlich ascites cells is one-third the Km of G-6-PDH for NADP+,
has been suggested to be a key regulatory factor in intact cell G-6-PDH activity [65]. Thus,
the extent to which G-P-PDH overexpression provides a means to drive NADPH
regeneration may depend on a variety of factors, e.g., the extent of the metabolic demand for
NADPH and the total available NADPH+NADP+ pool.
The intact sulf-treated cell NQO1 activity was more sensitive than the control cell activity to
extracellular glucose concentration. The sensitivity was manifested in the larger fraction of
NQO1 activity that relied on the presence of extracellular glucose and the pronounced
concentration dependence of the activity, across the entire 0 – 5.5 mM range of glucose
concentrations studied. The increased glucose sensitivity together with the pyridine
nucleotide data suggest that the induced NQO1 in the sulf-treated cells drives an increased
demand for pentose phosphate pathway generated NADPH, consistent with the demand
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imposed in other cell types by quinones [32-34]. This would be transmitted as an increased
demand for glucose-6-phosphate, relief of hexokinase product inhibition and stimulation of
glucose phosphorylation and transport. Since ATP was not depressed when NQO1 was
activated, glucose transport may be implicated as a factor limiting pentose phosphate
pathway catalyzed NADPH generation in the sulf-treated cells. A shift in metabolic control
from hexokinase to glucose transport in the sulf-treated cells could explain the higher Km for
both glucose (Figure 10) and DQ (Figure 2). This interpretation is suggested by studies in
neurons and other cell types in which the rate limiting step in glucose-6-phosphate
generation is inferred based on a presumptive difference in the Km for extracellular glucose
for glucose transport vs hexokinase activity [55]. However, the degree to which the control
point in glucose utilization under conditions of metabolic stress can be attributed to glucose
transport, hexokinase or other factors is a hotly debated topic, even in skeletal muscle where
it has been so extensively studied [66]. To the extent that intact cell NQO1-catalyzed DQ
reduction rates reflect not only processes regulating glucose-6-phosphate production, but
also downstream G-6-PDH activity, extends the candidate field for limiting factors, eg., to
free NADP+[65].
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The advantage of using an inducer to study the impact on functional intact cell NQO1
activity has translational relevance insofar as isothiocyanates are dietary derived substances
that promote anti-inflammatory, anti-carcinogenic, antioxidant function [20, 36-42]. This
sulforaphane effect to induce NQO1 in the pulmonary endothelial cells is consistent with its
known function as a potent phase II enzyme inducer in human microvascular and umbilical
vein endothelial cells, various lung cells, and other cells and organs [37-41, 49]. The
sulforaphane concentration used was in the present study was physiologically relevant
insofar as it was in the range of plasma concentrations achieved in studies of humans
consuming broccoli, a rich source of isothiocyanates, and lower than that measured in rat
plasma after oral dosing with sulforaphane at levels sufficient to induce phase II liver
enzymes [67, 68]. It was also reasonably close to concentrations that alter signal
transduction and other processes in vascular endothelial cells and induce phase II enzymes,
including NQO1, in human EAhy926 endothelial cells and rat lung slices [38, 40, 44-47].
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Our studies provide evidence that the NQO1 threshold may be at least in part attributed to a
limitation in the ability to regenerate NADPH at a sufficient rate to drive all the induced
NQO1 activity to its maximum rate. The dearth of studies of pulmonary endothelial
bioenergetics and pathways of pyridine nucleotide metabolism underscores the necessity for
additional studies in this area to promote understanding of responses to increased metabolic
demand in lung injury and repair. This is perhaps especially important with regard to the
pulmonary endothelium, which is exquisitely sensitive to oxidative stresses and in direct
contact with blood borne xenobiotics and toxins. Our studies provide the groundwork for
eventual evaluation of the utility of isothiocyanates and other phase II enzyme inducers as a
means to optimize the therapeutic efficacy of NQO1 targeted anticancer drugs and
antioxidants in the pulmonary endothelium, lung and other cell types and organ systems.
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Figure 1. NQO1 activity in intact control and sulf-treated cells measured in the extracellular
medium as DQ-mediated ferricyanide reduction
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The figure shows the ferricyanide concentration versus time progress curves following
addition of ferricyanide (600 μM) with DQ (1 - 50 μM) to the control (A) or sulf-treated (B)
cells. The effect of the competitive NQO1 inhibitor dicumarol (10 μM) at 50 μM DQ is
shown in (A) and (B). Also shown in (A) and (B) is the ferricyanide only data (without DQ).
The latter was subtracted as background from data obtained in the presence of DQ. For the
experiments without inhibitors, the symbols represent the data from 12 paired control and
sulf-treated cell experiments at 6 DQ concentrations, for which the cell proteins (mean ±
SEM in mg) were 1.19 + 0.03 (n = 72) and 1.00 ± 0.04 (n = 72), respectively (p < 0.05, ttest); cell proteins for dicumarol studies were 1.49 and 1.32 (n = 1 each) in (A) and (B)
respectively. The solid lines represent linear regression fits to the data. The % LDH release
measured at the end of each experiment did not exceed 1.58 ± 0.37% of total cell LDH for
all the studies combined, with no significant differences between conditions (p>0.05,
ANOVA).
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Figure 2. Effect of DQ concentration on NQO1 activity in intact control and sulf-treated cells
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The symbols represent the DQ reduction rates, calculated as described in the Methods from
the data in Figure 1, giving the intact cell NQO1 activities. Also shown are control and sulftreated cell DQ reduction rates at 1 – 50 μM DQ with dicumarol (10 μM) and the sulftreated cell DQ reduction rates at 1 – 50 μM DQ with ES936 (0.5 μM). The symbols
represent the mean ± SEM for n = 12 determinations each for control and sulf-treated cells,
and n = 1 each for dicumarol and ES936 conditions at each DQ concentration. The solid and
dashed lines are Michaelas-Menten fits to the data and the dotted line represents 5.7 times
the control activity across the full range of DQ concentrations. The control and sulf-treated
cell proteins are as in Figure 1, proteins for control and sulf-treated cells with dicumarol (n =
6 each) were 1.37 ± 0.06 and 1.41 ± 0.03, respectively, and for sulf-treated cells with ES936
(n=6), 1.03 ± 0.03. *Means are significantly different than control at the same DQ
concentration (p<0.05; t-test).
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Figure 3. Immunoblots of control and sulf-treated cell NQO1
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(A) Blot in which equivalent amounts of cell lysate (20 μg protein) were loaded onto each
lane, from 4 sets of control (C) and sulf-treated (S) cell cultures, wherein the individual sets
are from the 4 different cell populations. (B) Blot in which 10 times more control (20 μg)
than sulf-treated (2 μg) cell lysate protein was loaded onto each lane for 3 sets of control and
sulf-treated cell cultures, where the sets are from different populations. Human recombinant
NQO1 was the standard in both (A) and (B). (C) Total ng NQO1 protein (mean ± SEM) in
the control and sulf-treated cell lysates calculated from the lane intensities in blot (B). The
NQO1 standard was used for calibration as described in the Methods. (D) NQO1 protein per
mg cell lysate protein (mean ± SEM) calculated from the lane intensities in (B).
*Significantly different than control (p<0.05, t-test).
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Figure 4. Relationship between the sulforaphane-induced increase in intact cell and cell lysate
NQO1 activities
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(A) Maximal intact cell NQO1 activity (means ± SEM) of control and sulf-treated cells (n =
16 pairs control and sulf-treated cells, including all the Figure 1 data), studied at 50 μM DQ.
(B) Cell lysate NQO1 activity (means ± SEM) using DCPIP or DQ as the electron acceptor
in n = 16 or n = 4 pairs, respectively, of control and sulf-treated cells, with each pair derived
from the same passage studied in parallel on the same day. (C) The fold increase in intact
cell NQO1 activity, taken from (A) plotted vs the fold difference in cell lysate NQO1
activity, taken from (B), wherein the cell lysate data was obtained using either the DCPIP
(closed circles) or the DQ (open triangles) as the electron acceptor. The dashed line is the
line of identity, that is, the expected relationship if the intact cell activity rose in proportion
to cell lysate activity. *Significantly different than matched controls (p< 0.05, t-test).
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Figure 5. H2O2depresses maximum intact NQO1 activity in sulf-treated but not control cells

H2O2 (1 mM) was added to the cell medium 10 minutes prior to addition of DQ and
ferricyanide, and was also present throughout the 30 min period for measuring intact cell
NQO1 activity using the approach described in Figures 1 and 2. The symbols represent the
mean ± SEM from n=3 experiments for each of the 4 conditions. The cell proteins (mean ±
SEM, in mg) were as follows: control (1.03 ± 0.05), H2O2 (1.00 ± 0.04), sulf-treated (0.69 ±
0.03), sulf-treated + H2O2 (0. 70 ± 0.04). *Significantly different than sulforaphane-treated
(p<0.05, t-test).
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Figure 6. G-6-PDH inhibitor epiandrosterone (EPI) partially blocks NQO1 activity in intact
control and sulf-treated cells

Intact control and sulforaphane cell NQO1 activities were measured in the absence or
presence of EPI (30 μM). The bars represent the mean ± SEM for n=4 determinations for the
control ± EPI and n=5 for the sulf-treated cells ± EPI. LDH release for the control cells was
1.6 ± 0.17% and 2.14 ± 0.33% in the absence and presence of EPI, respectively (p>0.05, ttest); LDH release for the sulf-treated cells was 1.25 ± 0.05% and 2.6 ± 0.17% in the
absence and presence of EPI, respectively (p<0.05; t-test). The cell proteins (mean ± SEM,
in mg) for the controls ± EPI were 1.52 ± 0.03 mg and for the sulf-treated cells were 1.06 ±
0.10 mg). *Significantly different than without EPI (p<0.05, t-test).
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Figure 7. Impact of intact cell NQO1 activity on intracellular pyridine nucleotides in control and
sulf-treated cells

Fifteen min prior to KOH extraction for HPLC, cells were incubated in medium without (-)
or with (+) DQ (50 μM), the latter to elicit maximal intact cell NQO1 activity. Bars
represent means ± SEM of n=7 control without DQ and n=4 each for the other conditions.
*Significantly different than without DQ; † significantly different than control with DQ
(p<0.05; ANOVA and Tukey test for multiple pairwise comparisons).
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Figure 8. G-6-PDH gene overexpression increases G-6-PDH activity but is insufficient to increase
intact cell NQO1 activity in sulf-treated cells
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Effect of G-6-PDH gene overexpression (G6PDH) on cell lysate (A) G-6-PDH and (B)
NQO1 activities and on (C) intact cell NQO1 activities in control (mock transfected) and
sulf-treated cells. Bars represent mean ± SEM for n=5 for each condition. LDH release was
not significantly different for the different conditions, and the mean ± SEM for the
combined data was 2.53 ± 0.21 %. The cell proteins for the control, G6PDH, Sulf-treated
and G6PDH + Sulf-treated conditions were 1.52 ± 0.11, 1.36 ± 0.09, 0.96 ± 0.12 and 1.02 ±
0.12 (mean ± SEM) mg, respectively. (A) *Significantly different than without
overexpression; (B) and (C) †significantly different than controls or G6PDH without
sulforaphane (ANOVA; p<0.05, Tukey test).
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Figure 9. G-6-PDH gene overexpression does not alter pyridine nucleotide responses to NQO1
activation in either control or sulf-treated cells
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Fifteen min prior to KOH extraction for HPLC, cells were incubated in medium without (-)
or with (+) DQ (50 μM), the latter to elicit maximal intact cell NQO1 activity. Bars
represent means ± SEM of n=13 for G-6-PDH overexpression (G6PDH) without DQ and
n=10 each for the other conditions. *Significantly different than without DQ; † significantly
different than G6PDH with DQ; (p<0.05; ANOVA and Tukey test for multiple pairwise
comparisons).
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Figure 10. Increased sensitivity of sulf-treated cell NQO1 activity to limiting the extracellular
glucose concentration

Symbols represent mean ± SEM for 4 determinations for each condition. There was no
statistical difference (p > 0.05; t-test) between the %LDH release or protein for the control
and sulforaphane cells in the absence of glucose or at any glucose concentration studied. The
mean ± SEM for all 48 samples for % LDH release was 1.46 ± 0.11% and the protein was
1.20 ± 0.02 mg.
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